This is to inform that due to some circumstances beyond the organizer control, “2nd Edition of International Conference on Gastroenterology” (Gastro 2024) during October 21-23, 2024 at Baltimore, MD, USA has been postponed. The updated dates and venue will be displayed shortly.
Your registration can be transferred to the next edition, if you have already confirmed your participation at the event.
For further details, please contact us at gastroenterology@magnusconference.com or call + 1 (702) 988-2320.
Chronic liver disease (CLD) is a term used to describe a range of progressive liver conditions caused by a variety of factors including viruses, alcohol misuse, and genetic disorders. CLD can be further divided into two broad categories – cirrhosis and non-cirrhotic liver disease. Cirrhosis is a late-stage form of CLD in which healthy liver tissue is replaced by scar tissue, making it difficult for the liver to function properly. Non-cirrhotic CLD is usually less severe and may include fatty liver disease, autoimmune hepatitis, and other conditions. The most common symptom of CLD is fatigue, although other symptoms may include jaundice, abdominal pain, nausea and vomiting, itchy skin, and dark urine. CLD is a serious condition that can be life-threatening. The longer it goes untreated, the more severe the symptoms, and the more difficult it is to treat. The primary treatment for CLD is lifestyle changes, including quitting drinking alcohol, eating a healthy diet, managing stress, and getting regular exercise. In some cases, medications or surgery may be necessary. In addition, regular monitoring and follow-up care with a doctor is important for monitoring the progression of the disease and for checking for complications. CLD is a progressive condition and can be difficult to manage. However, with proper treatment, it can be managed and the progression of the disease can be slowed. It is important to talk to your doctor if you have any symptoms of CLD, as early diagnosis and treatment can help to improve quality of life and prevent further complications.
Title : Novel exosomal biomarkers for MASH
Aleksandra Leszczynska, University of California San Diego, United States
Title : Validation of GLAS (GP73+LG2m+Age+Sex) and ASAP (Age+Sex+AFP+PIVKA-II) algorithms for the management of liver fibrosis, cirrhosis and cancer
Philip M Hemken, Abbott Diagnostics Division R&D, United States
Title : Reverse multiple myeloma: First hepatic amyloidosis then multiple myeloma
Milaris M Sanchez Cordero, Mayaguez Medical Center, Puerto Rico
Title : Autophagy promotes the survival of adipose mesenchymal stem/stromal cells and enhances their therapeutic effects in cisplatin-induced liver injury via modulating TGF-1/Smad and PI3K/AKT signaling pathways
Eman Mohamad EL Nashar, King Khalid University, Saudi Arabia
Title : Epigastric Impedance measures gastric malfunction non-invasively. Time to revive it
John Andrew Sutton, Gastria Ltd, United Kingdom
Title : Digesting the connection: Exploring the psychological impact of gastroenterology issues on mental and emotional well being
Tracy E Hill, MGS Products LLC, United States